


GalNAc-T16, soluble fragment, Human Recombinant

| | | |
|----------------------------|--|------|
| CATALOG NO: | P1218-5 | 5 µg |
| ALTERNATE NAMES: | Polypeptide N-acetylgalactosaminyltransferase, Protein-UDP acetylgalactosaminyltransferase, GALNTL1, GALNT16 | |
| SOURCE: | Insect Cells | |
| PURITY: | > 90% by SDS - PAGE | |
| FORM: | Liquid | |
| FORMULATION: | Sterile filtered solution in 25 mM Tris pH 7.5 and 150 mM NaCl, at a stock concentration of 100 ug/ml. | |
| STORAGE CONDITIONS: | Stable for 4 weeks at 4°C. Stable for 6 months at -80°C. Avoid repeated freeze-thaw cycles. | |

DESCRIPTION: Polypeptide N-acetylgalactosaminyltransferase 16 (GalNAc-T16) catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of serine and threonine residues. Twenty GalNAc-T genes have been identified in humans and most have been shown to represent active GalNAc-Ts. All isoforms are type II transmembrane proteins, with different but partly overlapping substrate preferences. The GalNAc-Ts control the initiation of mucin-type O-linked glycosylation and determine the location and density of O-glycans in a protein. Addition of GalNAc to an unglycosylated Ser/Thr residue creates the Tn antigen GalNAc α 1-S/T, and subsequent addition of sialic acid by ST6GalNAc-I forms the cancer associated STn antigen.

RELATED PRODUCT:

- GalNAc-T2, soluble fragment, Human Recombinant (**Cat. No. P1215**)
- GalNAc-T3, soluble fragment, Human Recombinant (**Cat. No. P1216**)
- GalNAc-T5, soluble fragment, Human Recombinant (**Cat. No. P1217**)
- B3GNT6, soluble fragment, Human Recombinant (**Cat. No. P1219**)
- B4GalT1, soluble fragment, Human Recombinant (**Cat. No. P1220**)
- ST6GalNAc1, soluble fragment, Human Recombinant (**Cat. No. P1221**)
- ST3Gal1, soluble fragment, Human Recombinant (**Cat. No. P1222**)



FOR RESEARCH USE ONLY! Not to be used on humans.